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Abstract
This study addresses the molecular mechanisms underlying the action of subthalamic nucleus high frequency stimulation
(STN-HFS) in the treatment of Parkinson’s disease and its interaction with levodopa (L-DOPA), focusing on the striatum.
Striatal gene expression profile was assessed in rats with nigral dopamine neuron lesion, either treated or not, using agilent
microarrays and qPCR verification. The treatments consisted in anti-akinetic STN-HFS (5 days), chronic L-DOPA treatment
inducing dyskinesia (LIDs) or the combination of the two treatments that exacerbated LIDs. STN-HFS modulated 71 striatal
genes. The main biological processes associated with the differentially expressed gene products include regulation of
growth, of apoptosis and of synaptic transmission, and extracellular region is a major cellular component implicated. In
particular, several of these genes have been shown to support survival or differentiation of striatal or of dopaminergic
neurons. These results indicate that STN HFS may induce widespread anatomo-functional rearrangements in the striatum
and create a molecular environment favorable for neuroprotection and neuroplasticity. STN-HFS and L-DOPA treatment
share very few common gene regulation features indicating that the molecular substrates underlying their striatal action are
mostly different; among the common effects is the down-regulation of Adrb1, which encodes the adrenergic beta-1-
receptor, supporting a major role of this receptor in Parkinson’s disease. In addition to genes already reported to be
associated with LIDs (preprodynorphin, thyrotropin-releasing hormone, metabotropic glutamate receptor 4, cannabinoid
receptor 1), the comparison between DOPA and DOPA/HFS identifies immunity-related genes as potential players in L-
DOPA side effects.
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Introduction
The degeneration of nigrostriatal dopamine neurons is a main
pathological feature of Parkinson’s disease (PD) [1]. This leads to
alterations in the basal ganglia and hence to the motor disabilities
characterizing PD, such as akinesia [2]. The dopamine replace-
ment therapy using levodopa (L-DOPA) is the gold standard
pharmacological treatment of PD. After few years, the great
efficacy of this treatment is most often compromised by the
development of disabling motor complications that gradually
worsen, including motor fluctuations and L-DOPA-induced
dyskinesias (LIDs). Progress in the knowledge of the mechanisms
underlying LIDs, in particular of the cellular and molecular
changes occurring in the striatum, the main input station of the
basal ganglia, have opened new perspectives for their prevention
or alleviation [3–6].
The functional neurosurgical treatment by subthalamic nucleus
high frequency stimulation (STN-HFS) has demonstrated its
efficacy to alleviate main PD motor symptoms, allowing in most
cases a radical decrease of dopaminergic medication [7]. STN-
HFS then attenuates LIDs indirectly by reducing L-DOPA
requirement. There is evidence that this surgical treatment may
not have a direct antidyskinetic action. For instance, when
combined to dyskinesiogenic L-DOPA treatment, STN-HFS does
not improve but can even exacerbate LIDs in PD patients and
animal models [8–10]. As possible substrates, STN-HFS exacer-
bates L-DOPA-induced changes in several striatal markers
associated to LIDs [10] and prolongs the increase in extracellular
dopamine levels elicited by acute L-DOPA treatment [11]. There
is accumulating evidence that the action mechanisms of STN-HFS
are complex and that this surgical treatment might induce
duration-dependent adaptive changes, within and outside the
basal ganglia, and interfere with the disease progression [12]. In
particular, we previously provided evidence that prolonged STN-
HFS in PD model interferes with adult neurogenesis, promoting
survival of newly formed cells in the regions of constitutive
neurogenesis and also in the striatum [13]. Elucidating the
mechanisms of STN-HFS and its interaction with L-DOPA is
crucial, especially since up to recent trials, all PD patients selected
for HFS had a long history of L-DOPA treatment. Although the
striatum is not a primary target of STN, STN-HFS has been
reported to impact glutamate, GABA and dopamine striatal
neurotransmission, suggesting possible widespread action at
striatal level [12]. However, little is known about the striatal
molecular pathways implicated by STN-HFS.
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A number of studies have examined gene regulation in post-
mortem tissues of PD patients and in animal models, mostly in the
substantia nigra but also in the striatum. The effects of L-DOPA
treatment on striatal gene expression have been already addressed
[14–18] whereas the effects of STN-HFS have not been
investigated. In this study, gene array technology was used to
perform a large scale screening of the genes with altered striatal
expression in a rat PD model after antiakinetic subchronic STN-
HFS and L-DOPA treatment inducing dyskinesias, either sepa-
rately or in combination, in comparison with lesioned animals
without any treatment. The objectives were 1) to identify the
molecular signature of STN-HFS action at striatal level, associated
with its efficient antiparkinsonian action, and 2) to investigate the
molecular substrates of the interaction between the two treatments
in order to evidence possible genes involved in LIDs as STN-HFS
exacerbates LIDs. The pattern of genes modulated under STN-
HFS suggests that the neurosurgical treatment generates a
molecular environment that favors growth, neuroplasticity and
neuroprotection. Whereas wide changes occur after STN-HFS or
L-DOPA, few common regulations are found. Finally, comparison
of the genes modulated in the 3 experimental conditions suggests
an association between immunity-related genes and LIDs.
Materials and Methods
Experimental groups
All animal experimental procedures were carried out in strict
accordance with local rules concerning the use of laboratory
animals (authorization #B 13-267) and with the recommendations
of the EEC (86/609/EEC) for care and use of laboratory animals,
and conformed to the ethical guidelines of the French Ministry of
Agriculture and Forests (Animal Health and Protection Veterinary
Service). All animals used in this study were maintained on a
12:12-h light/dark cycle (lights on: 7:00 A.M. to 7:00 P.M.), with
food and tap water available ad libitum and every precaution was
taken to minimize the stress and the number of animals used in
each series of experiments. During surgery, wounds and pressure
points were repeatedly (every 2 h) infiltrated with lignocaine (2%).
Postoperative analgesia was performed by adding Acetaminophen
(400 mg/kg) in the drinking water during 7 days.
Microarray experiments were carried out on striatal tissue from
four groups of animals bearing 6-hydroxydopamine (6-OHDA)-
induced lesion of the nigrostriatal DA pathway: lesion alone
without any subsequent treatment (6-OHDA), dyskinesiogenic L-
DOPA treatment for 19 days (DOPA), STN-HFS for 5 days (HFS)
and combination of dyskinesiogenic L-DOPA and STN-HFS
(DOPA/HFS); in this last group HFS was applied during the 5 last
days of the 19-days L-DOPA treatment. Quantitative RT-PCR
was performed on striatal tissue from 2 additional groups of
lesioned animals either stimulated or not, 6-OHDA group and
HFS group, and a group of unlesioned rats with an electrode
implanted (control). Each experimental group for the microarray
study contained 3 animals, and for RT-qPCR 4 to 5 animals.
Surgery and treatment
Surgery was performed under Equithesin anaesthesia (4 ml/kg).
Animals received a unilateral injection of 9 mg of 6-OHDA
(Sigma-Aldrich, St Quentin–Fallavier, France) dissolved in 4.5 mL
of 0.9% sterile NaCl containing 0.1% ascorbic acid, at a rate of
1 mL/min, in the left SNc. The stereotaxic coordinates of the
injection site were: anteroposterior +2.2 mm, lateral 2.0 mm and
dorsoventral +3.3 mm from the interaural, with the incisor bar at
+5.0 mm above the interaural plane, according to the rat
stereotaxic atlas by [19]. These animals were killed by decapitation
33 days after 6-OHDA lesion. Fourteen days after 6-OHDA
lesion, two groups of rats (DOPA and DOPA/HFS) received
chronic L-DOPA treatment for 19 days. This treatment consisted
of two injections per day, at a 12-h interval, of 25 mg/kg L-DOPA
and 12.5 mg/kg benserazide (Sigma–Aldrich) dissolved in 0.9%
NaCl. All L-DOPA-treated animals, with or without HFS,
received the last injection 12 h before killing by decapitation.
Fourteen days after the 6-OHDA lesion, the groups of rats to be
treated by STN-HFS (HFS and DOPA/HFS) were anaesthetized
by Equithesin i.p. injection and were unilaterally implanted with
one platinum-iridium electrode for deep brain stimulation in the
STN ipsilateral to the lesion side as described previously [10]. The
stereotaxic coordinates were taken averaging the interaural and
bregma coordinates [20]; from bregma, they were: anteroposterior
23.8 mm (equidistant from the two wires), lateral 2.4 mm,
dorsoventral 28.1 mm from the surface of the meninges. STN-
HFS was applied continuously for 5 days in freely moving rats,
starting 28 days after 6-OHDA lesion, under conditions proven
efficient for alleviating DA denervation-mediated akinesia [9,10].
Stimuli were delivered by a pulse generator and a stimulus
isolation unit (P2MP, Marseille, France), which gave rectangular
current pulses. The stimulation parameters were: frequency:
130 Hz; pulse width 80 ms; intensity 60 mA (which was about
twice below the threshold intensity provoking dyskinetic move-
ments of the contralateral forepaw [10]). HFS and DOPA/HFS
animals were killed by decapitation immediately after turning off
the stimulation.
Behavioral assessments
Animals of the control, 6-OHDA and HFS groups were scored
for akinesia of the contralateral forelimb by using the cylinder test.
In brief, animals were placed in a Plexiglas cylinder and,
immediately after, videotaped for 30 min to examine the
symmetry/asymmetry of their forepaw use during their explor-
ative behavior in this new environment. The numbers of contacts
made on the cylinder wall during this period with the ipsilateral
paw, the contralateral paw, and both paws (double contacts) were
determined; a double contact was scored as an ipsilateral contact
plus a contralateral contact. Akinesia was represented as forelimb
asymmetry, i.e. % contralateral minus % ipsilateral forepaw
contacts.
For quantification of LIDs, animals of the DOPA and DOPA/
HFS groups were videotaped for 2 h after the injection of L-
DOPA at day 14 and day 19 of the chronic treatment, which
corresponded respectively to the time point just before starting
STN-HFS and the last day of HFS treatment. Individual animals
were scored for 1 min every 10 min, from 10 to 120 min after the
injection of L-DOPA as reported previously [21]. Axial,
orolingual, and forelimb dyskinesias were scored using a scale
from 0 to 4 as defined previously [22].
Tissue preparation
Animals were killed by decapitation, the brain quickly removed,
immediately frozen on dry ice powder and stored at 280uC until
use. Brains were sectioned at 220uC using a cryostat. Part of the
striatum was cut in thin sections (12 mm) for histological analysis.
On the other part, the dorsal striatum was punched from thick
sections and samples pooled to obtain around 10 mg tissue for
RNA extraction. Thin 12 mm sections were also performed at
STN level to control the electrode placement.
Striatal Gene Profiling after STN-HFS
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Control of the DA lesion extent and electrode
implantation site
The loss of DA terminals in the striatum was assessed as an
index of the extent of the DA denervation by analysis of 3H-
mazindol binding to DA uptake sites on film autoradiograms, as
described previously [23]. The location of the stimulating
electrode in the STN was examined on fresh cryostat sections.
Animals showing a reduction of less than 285% in 3H-mazindol
binding or a misplaced electrode were not included in the
experimental groups presented above.
Transcriptomic analysis and reverse transcriptase
quantitative PCR (RT-qPCR)
Total RNA was extracted using the RNeasy Mini kit (Quiagen,
Courtaboeuf, France) according to the manufacturer’s instruc-
tions. RNA concentration was determined with a nanodrop ND-
1000 spectrophotometer (nanodrop technologies, Wilmington,
DE, USA) and the quality was evaluated with an Agilent
bioanalyzer (Agilent technologies, Santa Cruz, CA, USA). The
RNA samples selected for microarray and for real-time PCR
experiments had an .8.0 RNA integrity number on a scale of 10.
RNA was stored at 280uC until use.
For microarray experiments, amplification and fluorescent
labeling of RNA was performed with the kit LIRLAK one color
(Low Input RNA Linear Amplification Kit, Agilent) with starting
amounts of 200 to 400 ng of total RNA. cRNAs were hybridized
on Rat AGILENT 4644 K microarrays and, after adequate
washing, scanned with Agilent Microarray Scanner. All steps were
performed according to the manufacturer (Agilent Technologies,
Santa Cruz, CA, USA). All individual samples were hybridized
onto separate microarrays. Thus, 12 Agilent oligonucleotide
microarrays were used to compare the gene expression profiles
of 6-OHDA, HFS, DOPA and DOPA/HFS groups. Microarray
data were extracted and quantified with Feature extraction
software (Agilent). The AgiND R library was further used for
data diagnosis and normalization (http://tagc.univ-mrs.fr/tagc/
index.php/software/16). Diagnosis was based on boxplot, color-
coded images and MA plot, while normalization was performed
based on the quantile method. Statistical analysis was performed
using the TIGR MeV (MultiExperiment Viewer) v4.1 software
(http://www.tm4.org/mev.html) and the GeneANOVA pro-
grams. First, a global ANOVA model gives an estimation of the
contribution of HFS and DOPA in the total variation of the whole
data set; gene was considered a factor in this model [24]. Genes
showing significant differential expression between the 4 experi-
mental groups were determined by a multi-class analysis using
Significance Analysis of Microarrays (SAM) of TMev with 100
permutations. Hierarchical cluster analysis was applied to these
genes in order to identify samples with similar profiles. Genes with
.1.2 or ,0.8 fold change in the HFS, DOPA and DOPA/HFS
groups compared to 6-OHDA were further analyzed using two
statistical tests. A two-class unpaired SAM of TMev with 20
permutations was first performed, with adaptive false discovery
rate (FDR) procedure [25]. FDR was ,10% for HFS and DOPA
(6 and 1%, respectively) and was 13% for DOPA/HFS due to
individual variability in this group. From these genes, those which
did not reach significance with a second statistical test, the non-
parametric Wilcoxon test (with p,0.05) were then subtracted.
Annotation of the significantly altered genes was performed using
DAVID database (http://david.abcc.ncifcrf.gov/) [26]. This
program was used to assess whether gene ontology (GO) terms
and the Kyoto Encyclopaedia of Genes and Genomes (KEGG)
pathways were overrepresented among the differentially expressed
genes and within specific gene clusters. A score based on Fisher’s
exact test reflected the probability that the prevalence of a
particular term within a cluster was due to chance alone, given the
prevalence of that term in the population of all genes under study.
For RT-qPCR validation of microarray data, six of the genes
showing differential expression in the HFS vs 6-OHDA group by
microarray analysis and an endogenous reference gene, hypoxan-
thine phosphoribosyltransferase (HPRT) were evaluated in con-
trol, 6-OHDA and HFS groups. Gene specific primers were
designed using Universal ProbeLibrary (ProbeFinder version 2.45
for rat, Roche Diagnostics) and chosen intron-spanning when
possible (Table S1). Total RNA (0.5 mg) was reverse transcribed
for 60 min at 42uC using ImProm-IITM reverse transcriptase
(Promega, Charbonnie`res-les-Bains, France) with random hexa-
mers. Real-time qPCRs were carried out in a total volume of 20 ml
using 1/100 of the cDNA produced by reverse transcription,
SsoFast EvaGreen Supermix (BioRad) and primer pair of the gene
of interest (eurofins operon) using Bio-Rad CFX96 cycler with the
following cycling parameters: 1 cycle at 95uC for 30 s (enzyme
activation); 40 cycles at 95uC for 10 s followed by 60uC for 30 s
(denaturation and annealing). Samples were run in duplicate for
each gene analyzed. Primer pairs were tested for specificity with
the melting curve analysis (0.5uC increment from 55uC to 95uC).
PCR efficiency laid around 110% for all the primers used. Ct
values for the reference and for the target genes were in similar
ranges and Ct for the reference was not changed among
experiments; furthermore HPRT expression analyzed by micro-
array also revealed no difference between all the samples,
confirming the validity of HPRT as a reference gene. Several
no-template controls, which produced no signal, were also
included. Relative target gene concentration was calculated using
the 22DDCt method which uses normalization to endogenous
reference gene and normalization to calibrator sample (here, mean
of the 3 values of the 6-OHDA group). Data were analyzed by
ANOVA with a Fisher test. The differences were defined as
significant when p,0.05.
Results
Control of the 6-OHDA-induced denervation extent in
the striatum and of the electrode location in STN
The selected 6-OHDA animals included in the four experi-
mental groups showed an extensive striatal dopamine denervation,
as assessed by the marked loss of 3H-mazindol binding in the
ipsilateral striatum vs controls (6-OHDA: 291.2962.76%; HFS:
288.3263.03%; DOPA: 295.03 60.92%; DOPA-HFS:
290.6662.19%). Figure 1 illustrates the correct location of the
stimulating electrode in the STN in the selected animals.
Behavioral observations
In the cylinder test, control animals equivalently use their right
and left forepaws (Figure 2A). Animals of the 6-OHDA group and
of the HFS group tested before starting the stimulation (pre-HFS)
showed a marked asymmetry, the number of contralateral contacts
being markedly reduced due to akinesia. This deficit is partially
but significantly reversed after 5 days of HFS in the HFS group
(HFS ON).
L-DOPA-treated animals in the DOPA and the DOPA/HFS
groups presented almost no axial dyskinesias, so that scores were
established based on orofacial and forelimb dyskinesias. The
dyskinesia score (Figure 2B) was relatively low in the DOPA group
(3.6760.58) and was significantly higher in the DOPA/HFS
group (5.3360.58) in agreement with previous data showing that
STN-HFS exacerbates LIDs [10,27].
Striatal Gene Profiling after STN-HFS
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Global gene analysis of the four groups: 6-OHDA, HFS,
DOPA and DOPA/HFS
We performed a gene profiling study using 44000 oligonucle-
otide microarrays to investigate the striatal effect of STN-HFS, of
DOPA treatment and of the combined STN-HFS/DOPA
treatment. The data obtained have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series
accession number GSE43375 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc =GSE43375).
The global gene ANOVA analysis demonstrated a very
significant effect of the different treatments with p value less than
1025 (Table S2). Hierarchical cluster analysis (Figure 3) was used
to test if changes in gene expression levels segregate the
experimental groups. It showed two clusters of samples with
similar gene profiles: one regrouped the samples from the 6-
OHDA animals without treatment (L) and the other gathered
together the samples from all the treated animals. The samples
from treated animals further clustered in two sub-groups, the first
one including the DOPA and DOPA/HFS samples (D and DS,
respectively, except one dopa-treated animal) and the second one
the three HFS samples (S). These results demonstrate that HFS
and L-DOPA treatments strongly affect gene expression in the
striatum and that the gene expression profile in the combined
treatment condition was close to that of DOPA treatment alone
and not to that of HFS alone.
Genes differentially expressed in HFS, DOPA and DOPA/
HFS versus 6-OHDA
The numbers of genes differentially expressed in each of the
three treatment groups as compared to 6-OHDA are presented in
Figure 4. Of the 71 genes showing differential expression in the
HFS group (listed in Table S3), twice as many were down-
regulated than up-regulated. More genes, 167, were affected in the
DOPA group (Table S4), with equivalent numbers being down-
regulated and up-regulated. Because of individual variability, only
26 genes were found in the DOPA/HFS group (Table S5), most
being down-regulated. To note however that several of the genes
induced by L-DOPA and reported to be associated with LIDs,
such as Pdyn (preprodynorphin) and Trh (thyrotropin-releasing
hormone) show a clear tendency towards upregulation in the
DOPA/HFS group (respectively 1.660.5 and 2.561.4 fold
change vs 6-OHDA).
Only five genes were commonly regulated by all the treatments,
3 being down-regulated: Adrb1 (b1-adrenergic receptor), Btg2 (B-
cell translocation gene 2), and Sirt5 (sirtuin 5), and 2 up-regulated:
Galntl5 (polypeptide N-acetylgalactosaminyltransferase-like 5) and
Ngfr (Nerve growth factor receptor). Two more genes were found
in common for HFS and DOPA/HFS: Carhsp1 (calcium-regulated
heat stable protein 1) and Ebf1 (early B-cell factor 1), 3 for DOPA
and DOPA/HFS: C1s (complement C1s subcomponent), Rt1-Da
(RT1 class II, locus Da) and Irf7 (interferon regulatory factor 7) and
12 for HFS and DOPA: bbc3 (bcl-2 binding component 3, also
called PUMA), emp3 (epithelial membrane protein 3), geft/Arhgef25
(rho guanine nucleotide exchange factor 25), itpka (Inositol-1,4,5-
trisphosphate 3-kinase A), loc683470 (similar to growth arrest
specific 1), loc684626 (similar to K11B4.2), loc688966/Mef2bnb
(MEF2B neighbor), nr4a3 (nuclear receptor subfamily 4 group A
member 3), prkcb (protein kinase C beta type), prkcd (protein kinase
Figure 1. Photomicrograph illustrating the electrode place-
ment in the STN. Subthalamic nucleus was outlined by the white
dotted line. The black arrows show the location of the bared electrode
tips delivering HFS in the STN. CP, cerebral peduncle.
doi:10.1371/journal.pone.0060447.g001
Figure 2. STN HFS alleviates akinesia and exacerbates L-DOPA-induced dyskinesia. (A) Akinesia was assessed by forelimb asymmetry in
the cylinder test in the control and 6-OHDA groups and in the HFS group before the stimulation (pre-HFS) and after 5 days of stimulation (HFS-ON).
Forelimb asymmetry was calculated as the % contralateral minus % ipsilateral forepaw contacts (*p,0.05 HFS ON vs. pre-HFS). (B) Analysis of AIMs
was performed in DOPA and DOPA/HFS groups. Dyskinesia score corresponds to the sum of the orolingual and forelimb AIM scores (maximum 8).
The data are the means 6 SEM, *p,0.05 DOPA/HFS vs DOPA.
doi:10.1371/journal.pone.0060447.g002
Striatal Gene Profiling after STN-HFS
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C delta type), slc18a2 (vesicular monoamine transporter 2), trpc4
(short transient receptor potential channel 4). To note that emp3
and PrKcd were inversely regulated by HFS and by DOPA.
From the genes significantly altered in HFS group vs 6-OHDA
(Table S3), 5 displayed a more than 2-fold increase: Ttr
(transthyretin), Sostdc1 (sclerostin domain containing 1), Aqp1
(aquaporin 1), Nr4a3 and Igf2 (insulin growth factor 2); Ttr and
Sostdc1 showing the highest fold change: 279 and 26, respectively.
The up-regulation of Ttr, Sostdc1 and Igf2 was verified by RT-
qPCR (Figure 5A). RT-qPCR also confirmed the more modest
(1.4-fold) up-regulation of Chrna7 (nicotinic receptor alpha 7
subunit) found in microarray analysis. The PCR analysis showed
that these 4 genes were not differentially expressed in 6-OHDA
and control conditions, and were thus up-regulated by HFS vs
control. In the microarray, these 4 genes were not modified in
DOPA and DOPA/HFS conditions, suggesting that part of the
Figure 3. Hierarchical clustering. The 12 experimental striatal samples were: L1, L2 and L3 (6-OHDA); S1, S2 and S3 (HFS); D1, D2 and D3 (DOPA)
and DS1, DS2 and DS3 (DOPA/HFS). The hierarchical clustering was constructed with the genes showing significant changes after a 4 group Sam
analysis on the genes with expression value above detection limit in at least 40% of the samples. Upregulated and down-regulated genes appear in
red and in green, respectively, with the relative log2 (ratio) reflected by the color intensity. Three sample clusters were found: 6-OHDA, DOPA with
DOPA/HFS and HFS.
doi:10.1371/journal.pone.0060447.g003
Striatal Gene Profiling after STN-HFS
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HFS effects was lost when combined to L-DOPA treatment.
Genes that were down-regulated vs 6-OHDA in HFS condition
included Prkcd, which, in agreement with previous data [14] was
up-regulated in the DOPA group (Figure 5B). Prkcd expression was
unaffected in the DOPA/HFS, suggesting an addition of the
opposite effects of the two treatments. We validated by RT-qPCR
the down-regulation of Prkcd by HFS vs 6-OHDA (Figure 5B);
since the PCR experiment showed that the Prkcd gene expression
was lower in control vs 6-OHDA, we concluded that HFS, in fact,
normalized the expression of this gene. In microarrays, one of the
genes showing the more marked down-regulation by HFS was
Sirt5, a gene also down-regulated in the DOPA and DOPA/HFS
groups (Figure 5C). The decrease of Sirt5 by HFS did not reach
significance (p = 0.10) in the RT-qPCR analysis; this analysis
further indicated that this gene was overexpressed in 6-OHDA vs
control, suggesting tendency towards normalization by the
treatments. Overall, we found very similar fold change values by
microarray and RT-qPCR analysis, although these measurements
were made in different experimental series of animals.
Biological analysis of genes altered by HFS, DOPA and
DOPA/HFS
In order to understand the biological meaning of the gene lists
found in the previous analysis, we used DAVID bioinformatics
resources that allow the identification of the most relevant
(overrepresented) biological terms/functions associated with a
gene list and the clustering into functionally related gene groups on
the basis of their associated biological processes (BP), cellular
components (CC) and molecular functions (MF). For the genes
differentially expressed after HFS, 127 functional groups were
identified (Table S6). Table 1 presents 8 functional groups selected
from this list, as being highly significant, representative of several
categories, or presumably related to PD after a detailed
bibliographic search. The BP GO terms were ‘‘response to
endogenous stimulus’’ (12 genes), ‘‘ion transport’’ (12 genes),
‘‘regulation of growth’’ (9 genes), ‘‘positive regulation of apoptosis’’
(10 genes), ‘‘regulation of synaptic transmission’’ (6 genes),
‘‘regulation of BMP signaling pathway’’ (3 genes), and ‘‘regulation
of MAPKKK cascade’’ (4 genes); the CC GO term was
‘‘extracellular region’’ (10 genes). PD-related genes included in
these functional groups were Ngfr, Igf2, Prkcd, Chrna7 and Mapk8
(mitogen-activated protein kinase 8). Ttr and Sostdc1, the two genes
that displayed the higher level of induction after STN-HFS, shared
the same GO term ‘‘extracellular region’’, in compliance with
their role as extracellular regulators of multiple signaling pathways.
The most enriched GO terms found after DOPA and DOPA/
HFS are presented in Tables S7 and S8. Interestingly, several
common GO terms related to immunity were over-represented
after these treatments but never found after HFS alone. From the
eight genes significantly altered in both DOPA and DOPA/HFS
groups, three genes were involved in immune responses: C1s and
Rt1-Da were up-regulated and Irf7 was down-regulated.
Two KEGG metabolic pathways involved in the striatal effect of
HFS were identified (Table 2). The first one, ‘‘calcium signaling
pathway’’, grouped together 5 genes among which Chrna7,
encoding the a7-nicotinic acetylcholine receptor, which has been
notably involved in the neuroprotective action of nicotine for
dopamine neurons. The second one is ‘‘type II diabetes mellitus’’;
interestingly, there are reports suggesting a link between this
pathology and PD [28]. Three KEGG pathways were identified
after L-DOPA treatment: ‘‘neuroactive ligand-receptor interac-
tion’’, ‘‘calcium signaling pathway’’, and ‘‘ECM-receptor interac-
tion’’. Some of the genes from these pathways are related to non-
dopaminergic transmitter systems that have been implicated in
LIDs, such as Adra2b and Adrb1 (encoding adrenergic alpha 2 and
beta1 receptors), Htr2c (5-hydroxytryptamine/serotonin receptor
2C), Cnr1 (cannabinoid receptor 1 or CB1). Several genes in the
calcium pathway underwent similar down-regulation under HFS
and DOPA, suggesting that their regulation might be associated
rather to the beneficial effects of these treatments than to LIDs.
The genes clustered in the ‘‘ECM-receptor interaction’’ pathway
include Sdc1 (syndecan 1) and genes encoding integrins and type V
collagen. Only one KEGG pathway, ‘‘calcium signaling path-
way’’, was found when testing the genes differentially regulated in
the striatum of rats after DOPA/HFS (Table 2). This pathway was
thus common to the 3 treatment groups although the genes
regulated were mostly not the same, except Adrb1 which was
similarly regulated in the 3 treatment conditions.
Discussion
Molecular mechanisms underlying the action of
subchronic STN-HFS
Several genes involved in neuroplasticity or neuroprotection
were altered under STN-HFS (Table 3).
STN-HFS and plasticity-associated genes. A main finding
from this study is the drastic increase in Ttr expression induced
specifically by STN-HFS. Transthyretin (TTR) is mostly known as
a carrier of thyroxin and indirectly of retinol via binding to the
retinol-binding protein. Until recently, the only site of TTR
synthesis in the brain was thought to be the choroid plexus, but
evidence has been provided that neurons transcribe TTR mRNA
[29]. Decreased TTR expression during aging has been associated
with reduced availability of the retinol-derived retinoic acid (RA)
and with memory deficit [30]. RA is an important morphogen in
brain development, especially in striatal neuron differentiation
[31], and a key regulator of neuroplasticity in adult brain,
including normal adult neurogenesis and post-stroke striatal
neurogenesis [32,33]. It is therefore of interest to associate the
Ttr upregulation shown here with our previous finding that similar
subchronic STN-HFS promotes newly-formed cell survival, not
only in the regions of constitutive neurogenesis, but also in the
striatum [13]. Recently, TTR has been shown to act as a
metallopeptidase [34] with 3 natural substrates identified, apoA-1,
neuropeptide Y and Ab. Interestingly, neuropeptide Y is expressed
in a population of striatal GABA interneurons [35] and is
upregulated in the striatum in PD patient [36] and rat PD model
[37,38]. By preventing the formation of amyloid beta fibrils, TTR
may also play a neuroprotective role in degenerative diseases such
Figure 4. Venn diagram showing the numbers of genes
specifically or commonly altered by the treatments.
doi:10.1371/journal.pone.0060447.g004
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Figure 5. Comparison of the data obtained by microarray and RT-qPCR for 6 genes of interest. (A) Genes specifically up-regulated by
HFS, (B) opposite regulation of Pkrcd by HFS and DOPA and (C) common down-regulation of Sirt5 by HFS and DOPA. Microarray experiments were
performed on total striatal RNA samples from 6-OHDA, HFS, DOPA and DOPA/HFS groups. For qPCR validation of gene expression, total striatal RNA
samples from 3 groups were analyzed: control, 6-OHDA and HFS. For both microarray and qPCR, results were calculated for each sample relative to
the expression of the endogenous reference gene: HPRT, and fold change vs the 6-OHDA group was determined using the 22DDCt method. Values are
presented as means 6 SEM. *p,0.05 vs 6-OHDA values.
doi:10.1371/journal.pone.0060447.g005
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Table 1. Enriched functional categories (GO terms) for genes differentially expressed after HFS vs 6-OHDA, with the constituting
genes and their fold change (FC).
Gene symbol Gene name FC
GOTERM_BP, Response to endogenous stimulus, p value 3.1025
Aqp1 aquaporin 1 3.3
Nr4a3 nuclear receptor subfamily 4, group A, member 3 2.7
Igf2 insulin-like growth factor 2 2.0
Rpe65 retinal pigment epithelium 65 1.4
Mapk8 mitogen-activated protein kinase 8 1.2
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 0.8
Slc18A2 solute carrier family 18 (vesicular monoamine), member 2 0.8
Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit 0.8
Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 0.7
Gnb1 guanine nucleotide binding protein (G protein), beta polypeptide 1; guanine nucleotide binding
protein (G protein), beta polypeptide 4
0.7
Btg2 B-cell translocation gene 2, anti-proliferative 0.6
Prkcd protein kinase C, delta 0.6
GOTERM_BP, Ion transport, p value 1.2.1024
Aqp1 aquaporin 1 3.3
Slc4A2 solute carrier family 4 (anion exchanger), member 2 1.5
Chrna7 cholinergic receptor, nicotinic, alpha 7 1.3
Slc12a4 solute carrier family 12 (potassium/chloride transporters), member 4 1.2
Tcirg1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 0.8
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 0.8
Trpc4 transient receptor potential cation channel, subfamily C, member 4 0.8
Prkcb protein kinase C, beta 0.8
Slc39A8 solute carrier family 39 (metal ion transporter), member 8 0.8
Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit 0.8
Cacnb2 calcium channel, voltage-dependent, beta 2 subunit 0.7
Prkcd protein kinase C, delta 0.6
GOTERM_BP, Regulation of growth, p value 3.1024
Htra1 HtrA serine peptidase 1 1.4
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.3
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 0.8
Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 0.8
Prkcb protein kinase C, beta 0.8
Adrb1 adrenergic, beta-1-, receptor 0.7
Gpc3 glypican 3 0.7
Bbc3 Bcl-2 binding component 3 0.5
GOTERM_BP, Positive regulation of apoptosis, p value 5.5.1024
Pdia3 protein disulfide isomerase family A, member 3 1.5
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.3
Ngfr nerve growth factor receptor (TNFR superfamily, member 16) 1.3
Mapk8 mitogen-activated protein kinase 8 1.2
Tradd TNFRSF1A-associated via death domain 0.8
Aph1a anterior pharynx defective 1 homolog A (C. elegans); similar to Gamma-secretase subunit
APH-1A (APH-1a) (Aph-1alpha) (Presenilin-stabilization factor)
0.7
Prkcd protein kinase C, delta 0.6
Bbc3 Bcl-2 binding component 3 0.5
GOTERM_BP, Regulation of synaptic transmission, p value 7.5.1024
Chrna7 cholinergic receptor, nicotinic, alpha 7 1.3
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.3
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as Alzheimer disease [29]. In connection with PD, Ttr is
upregulated at a pre-manifest stage in the SNc of MPTP-treated
monkeys [39] and in the striatum of mice overexpressing human
a-synuclein gene [40], suggesting a role in compensatory
processes. Ttr is also upregulated in response to nicotine [41],
which, according to epidemiological data and studies in animal
models, may protect against PD [42]. Based on these data, the
increase in striatal Ttr gene expression found here under
subchronic STN-HFS might be part of a molecular pathway
underlying neuroprotective/neuroadaptative effects of this surgical
treatment.
Several other genes, involved in neuroplasticity are shown here
to be also upregulated by STN-HFS: Igf2, Sostdc1 and Nr4a3.
Among these, only Nr4a3 is also upregulated by L-DOPA. Igf2
encodes the secreted growth factor IGF2 that has been suggested
to have neurotrophic effects, promoting survival and differentia-
tion of neuronal cell [43], to modulate neuronal plasticity and to
regulate adult neurogenesis in the hippocampus [44]. Interestingly,
IGF2 has been pointed as part of a combination of 4 factors
sufficient to promote differentiation of human embryonic stem
cells to functional midbrain DA neurons [45]. Moreover, IGF2
was recently identified as a potent modulator of synapse density
and spine morphology in mature hippocampal neurons [46].
Striatal spine loss is a key pathological feature of Parkinson’s
disease [47]. Whether or not STN-HFS might restore synaptic
architecture at spines through IGF2-mediated mechanisms thus
deserves particular interest for future investigations.
The protein SOSTDC1 acts as a bone morphogenetic protein
(BMP) antagonist, as does NOGGIN that has been shown to
suppress the BMP-mediated pro-gliogenic signaling and promote
the differentiation/recruitment of neurons in the adult striatum
[48,49].
Nr4a3 is upregulated by STN-HFS and L-DOPA treatments,
with a prominent increase under HFS. NR4A3 is a member of the
NR4A family of nuclear receptors [50], which depending on their
level of expression and subcellular localization are involved in
differentiation, survival and apoptosis. Induction of Nr4a3 gene has
been associated to neuroleptic-mediated striatal responses [51] and
suggested to regulate tyrosine hydroxylase and dopamine trans-
porter DAT [52] suggesting a role in DA transmission at post- and
pre-synaptic level.
Another gene of interest specifically regulated by STN-HFS is
Ebf1. Ebf1 is one of the 2 genes commonly down-regulated in the
HFS and DOPA-HFS conditions. It is a member of a family of
transcription factors implicated in the coupling of neuronal
differentiation with cell cycle exit and possibly stabilization of
the committed state [53]. EBF1 has been demonstrated to be a
lineage-specific transcription factor critical to the differentiation of
striatonigral neurons [54] that form the D1 receptor-expressing
direct pathway. Imbalanced activity between this pathway and the
D2R-expressing indirect pathway is an essential pathophysiolog-
ical feature of PD. How is the down-regulation of Ebf1 by STN-
HFS impacting the striatonigral pathway is an intriguing issue that
would deserve further investigation.
Table 1. Cont.
Gene symbol Gene name FC
Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit 0.8
Adrb1 adrenergic, beta-1-, receptor 0.7
Edn1 endothelin 1 0.7
Bhlhe40 basic helix-loop-helix family, member e40 0.5
GOTERM_BP, Regulation of BMP signaling pathway, p value 4.9.1023
Sostdc1 sclerostin domain containing 1 25.9
Htra1 HtrA serine peptidase 1 1.4
Gpc3 glypican 3 0.7
GOTERM_CC, Extracellular region, p value 5.4.1023
Ttr transthyretin 278.7
Sostdc1 sclerostin domain containing 1 25.9
Igf2 insulin-like growth factor 2 2.0
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.3
Prelp proline arginine-rich end leucine-rich repeat protein 1.2
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 0.8
Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 0.7
Vtn vitronectin 0.7
Edn1 endothelin 1 0.7
Gpc3 glypican 3 0.7
GOTERM_BP, Regulation of MAPKKK cascade, p value 1.5.1022
Igf2 insulin-like growth factor 2 2.0
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.3
Edn1 endothelin 1 0.7
Prkcd protein kinase C, delta 0.6
Abbreviations: GO: gene ontology; BP: biological process; CC: cell. component.
doi:10.1371/journal.pone.0060447.t001
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STN-HFS and genes associated to cell death or
neuroprotection. Several genes possibly involved in cell
death/apoptosis are down-regulated by STN-HFS Prkcd, Bbc3,
Sirt5, whereas Chrna7 presumably involved in neuroprotection is
upregulated. Modulation of these genes may then be part of
striatal adaptive processes promoting survival of newly-formed
striatal cells [13], protecting striatal neurons, or contributing, at
axon terminal level, to the previously reported neuroprotective
effects of STN surgery on nigral DA neurons [51–54] and to
increased metabolism of spared DA neuron [55–57].
PRKCD transcriptional upregulation is implicated in oxidative
stress-induced neuronal cell death [58]. Conversely, pharmaco-
logical inhibition of PRKCD or depletion by siRNA is sufficient to
prevent dopaminergic neurodegeneration in PD models [59,60]
pointing to PRKCD inhibition as a neuroprotective strategy for
PD. It is to note that Prkcd is one of the two genes oppositely
Table 2. KEGG metabolic pathways for genes differentially regulated in HFS, DOPA and DOPA/HFS groups vs 6-OHDA.
Gene symbol Gene name
HFS vs 6-OHDA
Calcium signaling pathway, p value 0.026
Adrb1 adrenergic, beta-1-, receptor
Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit
Chrna7 cholinergic receptor, nicotinic, alpha 7
Itpka inositol 1,4,5-trisphosphate 3-kinase A
Prkcb protein kinase C, beta
Type II diabetes mellitus, p value 0.037
Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit
Mapk8 mitogen-activated protein kinase 8
Prkcd protein kinase C, delta
DOPA vs 6-OHDA
Neuroactive ligand-receptor interaction, p value 0.02
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C
Mas1 MAS1 oncogene
Adra2b adrenergic, alpha-2B-, receptor
Adrb1 adrenergic, beta-1-, receptor
Agtr1a angiotensin II receptor, type 1a
Cnr1 cannabinoid receptor 1 (brain)
Crhr1 corticotropin releasing hormone receptor 1
Grm4 glutamate receptor, metabotropic 4
Hcrtr1 hypocretin (orexin) receptor 1
ECM-receptor interaction, p value 0.02
Col5a2 collagen, type V, alpha 2
Col5a3 collagen, type V, alpha 3
Itga7 integrin alpha 7
Itgb6 integrin, beta 6
Sdc1 syndecan 1
Calcium signaling pathway, p value 0.03
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1
Adrb1 adrenergic, beta-1-, receptor
Agtr1a angiotensin II receptor, type 1a
Itpka inositol 1,4,5-trisphosphate 3-kinase A
Prkcb protein kinase C, beta
Ppp3r1 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I)
DOPA/HFS vs 6-OHDA
Calcium signaling pathway, p value 0.05
Adrb1 adrenergic, beta-1-, receptor
Chrm3 cholinergic receptor, muscarinic 3
Tnnc2 troponin C type 2 (fast)
doi:10.1371/journal.pone.0060447.t002
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regulated by STN-HFS and L-DOPA; its upregulation by L-
DOPA complies with previous report [14] and supports pro-
oxidant property of L-DOPA at high dosage inducing dyskinesia.
BBC3 is a pro-apoptotic protein, acting as main regulator of
oxidative stress and neuronal apoptosis and has been proposed as a
target for the treatment of neurodegenerative conditions [61]. In
connection to PD, induction of Bbc3 has been involved in 6-
OHDA-induced cell death mechanisms [62]. Sirt5, encodes a
mitochondrial isoform of sirtuins, a family of NAD+-dependent
protein deacetylases [63]. Growing evidence suggests that sirtuins
are involved in neuronal survival, with however opposite effects:
for instance, whereas Sirt1 is generally considered as neuropro-
tective, a recent report shows that mitochondrial Sirt5 can
promote neuronal death [64]. Finally, our study evidences STN-
HFS-induced upregulation of a7-nicotinic acetylcholine receptor
gene (Chrna7). In addition to its role in the modulation of specific
neurotransmitters and as a central regulator of inflammatory
processes, CHRNA7 (a7 nAChR) has been involved in neuropro-
tection following various insults. In particular, it has been reported
to mediate the neuroprotective effect of nicotine on dopaminergic
neurons [65]. These receptors are expressed in a high percentage
of the striatal cholinergic interneuron population [66], the only
known source of acetylcholine in the striatum. Also few in
numbers, these interneurons are important regulators of striatal
function. Interestingly, activation of a7 nAChRs has been shown
in hippocampus to increase Igf2 expression [67], and nicotine, as
reported above, to increase Ttr expression, suggesting a link
between up-regulation of these 3 genes in a neuroprotective
mechanism.
Finally, STN-HFS also upregulates Ngfr and down-regulates
Btg2 and Carhsp1. Ngfr encodes the p75 neurotrophin receptor
(p75NTR) and has been involved in both pro-apoptotic and
prosurvival processes through multiple signaling cascades depend-
ing on the cellular context [68]. Btg2 has been identified as part of
a set of activity-regulated inhibitor of death genes that mediates
acquired neuroprotection induced by synaptic activity, in partic-
ular pro-survival effect through synaptic NMDA receptors [69]. As
corticostriatal glutamate transmission is markedly increased after
dopamine lesion, it could be that this gene is upregulated as a
neuroprotection mechanism against excitotoxicity in PD state and
that its down-regulation by STN-HFS vs 6-OHDA found here is
linked to the previously reported suppression by STN-HFS of
overactive striatal glutamate transmission [9]. Carhsp1 is one of the
two genes commonly regulated in HFS and DOPA-HFS
conditions but not by DOPA alone. It encodes a cold-shock
domain-containing protein which has been recently identified as a
TNF-a mRNA stability enhancer required for effective production
of TNF- a, a central mediator of inflammation [70]. Carhsp1
down-regulation by STN-HFS might then also participate to
neuroprotection by reducing inflammation.
Genes not regulated by HFS potentially involved in L-
DOPA-induced dyskinesia
L-DOPA at a dose inducing dyskinesia is shown here to alter
numerous genes in the striatum, the great majority of which were
not modified by HFS alone applied with parameters efficiently
alleviating akinesia, without inducing dyskinesias. The upregula-
tion of Pdyn observed here is a consistent correlate of LIDs across
species and parkinsonian conditions [22,71–73] and is in
Table 3. Functional implications of the products of the genes differentially expressed after STN-HFS in link with neuroplasticity,
neurogenesis or neuroprotection.
NEUROPLASTICITY/NEUROGENESIS
Increased by STN-HFS, localization: extracellular
TTR transthyretin Transport of retinol Retinol regulates striatal neuron differentiation and adult neurogenesis
(post stroke striatal adult neurogenesis)
[31,32,33]
IGF2 Growth factor Involved in dopaminergic differentiation, adult neurogenesis;
modulator of spine morphology
[44,45]
SOSTDC1 BMP antagonist BMP antagonists are involved in differentiation/recruitment of
neurons in the striatum
[48,49]
Increased by STN-HFS, localization: nuclear
Nr4A3 Transcription factor NR4A gene expression is related to expression of dopamine
neurotransmission genes.
[52]
Decreased by STN-HFS, localization: nuclear
Ebf1 Transcription factor Involved in differentiation of striatonigral neurons [54]
NEUROPROTECTION
Increased by STN-HFS, localization: membrane or extracellular
CHRNA7 Binds Acholine/nicotine Involved in the neuroprotective effect of nicotine on
DA neurons; Increases IGF2
[65,67]
TTR Binds Ab,
Metallopeptidase
Prevents Ab amyloid fibril formation Degrades ApoA-1, NPY, Ab [29,34]
Decreased by STN-HFS, localization: intracellular
PRKCd Protein kinase PRKCd inhibition prevents dopaminergic neurodegeneration [59,60]
BBC3 Pro-apoptotic protein Involved in 6-OHDA-induced cell death [62]
SIRT5 NAD-dependent protein
deacetylase
Promotes neuronal death [64]
doi:10.1371/journal.pone.0060447.t003
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accordance with an over-activation of the direct striatal pathway.
Several modulated genes could contribute to the abnormal
glutamate transmission that has long been proposed to play a
role in LID [74,75]. This includes the decrease in Grm4 that
encodes metabotropic glutamate receptor 4 (mGlu4) and the
down-regulation of Ppp3r1, the calcineurin regulatory unit gene,
knowing that calcineurin function is closely related to NMDA-
receptor signaling and involved in dopamine-glutamate interac-
tions. In accordance with previous reports [14,76], gene expres-
sion of type 1 cannabinoid receptor (CB1), considered as a target
for antidyskinetic therapies, is upregulated. The largest and most
significant change induced by L-DOPA reported here and in
accordance with previous studies [15,77] is the upregulation of
Trh. This could be an essential feature of dyskinesias because the
intrastriatal injection of TRH induces abnormal movements,
apparently by increasing dopamine release. Finally, LIDs have
been shown to also involve the noradrenergic and serotonin
systems [78]. In this connection, we evidence a down-regulation of
striatal adrenergic alpha2 (a2bR or Adra2b) and serotonin 2C
(Htr2c or 5-Ht2c) receptor genes. Although these receptors have
been pointed as potential targets for LIDs [5,79], the direct link
between their down-regulation at striatal level found here and
LIDs mechanisms remains elusive. It is to note that several other
genes reported here have been already identified in previous
microarray studies on LIDs: Atp2b1, Arbp, Cdh22, Igfbp5, Itpka,
Itga7, Nefh, Ppp3ca, Prkcd, Rgc32, Rgs4, Scg2, Tnni3 [14–18].
Differentially expressed genes in the DOPA group also include
genes clustered in the KEGG pathway ECM-receptor interaction,
such as syndecan 1, a transmenbrane heparansulfate proteoglycan,
which has been notably involved in angiogenesis and in astrocytic
reactivity in response to brain injury. These genes could contribute
to LID-associated reorganizations, such as the previously reported
microvascular remodeling [80].
In our experiments, HFS exacerbates LIDs when applied with a
dyskinesiogenic L-DOPA treatment. We identified three novel
genes possibly associated with LIDs as they are commonly
modified in the DOPA and DOPA/HFS groups but unaffected
by HFS alone. These genes are involved in immune response: C1s
and Rt1-Da are up-regulated and Irf7 is down-regulated. Several
GO terms related to immunity are also found in common in L-
DOPA and L-DOPA/HFS and never found after HFS alone.
Increasing evidence support the involvement of innate and
adaptive immunity in PD progression [81]; altered immune
system in PD might in part be linked to an immunoregulatory role
of dopamine [82]. Whether the expression of LIDs might involve
an abnormal immune response then deserves further investigation.
On the other hand, a number of genes (15) are regulated only in
the DOPA/HFS condition and one cannot exclude their
contribution to the reinforcement of LIDs by STN-HFS. These
genes are quite all down-regulated and include the muscarinic M3
receptor and a subunit of the hyperpolarization-activated cyclic
nucleotide-gated potassium channels (HCN) that are responsible
for the i(h) current characterizing the cholinergic interneurons in
the striatum and underlying their tonic activity. Interestingly,
recent data have suggested that cholinergic neurons may play a
central role upstream of striatal projection neurons once LID is
established [83].
Genes commonly regulated by HFS and/or L-DOPA
The KEGG pathway ‘‘Calcium signaling pathway’’ is the only
one to be associated with the 3 treatment conditions. However,
there is a single gene commonly regulated in this pathway: Adrb1,
which encodes the adrenergic b1-receptor and which is down-
regulated. This finding supports a major role of these receptors in
PD pathophysiology. These receptors are highly expressed in the
striatum where their activation results in excitation of cholinergic
interneurons and medium spiny neurons through cAMP-depen-
dent pathway [84,85]. Their blockade has been suggested to
mediate the beneficial effects of propranolol on PD tremor and on
LIDs. Outside this KEGG pathway, there are few (4) other genes
commonly regulated under the 3 treatment conditions, among
which btg2, Sirt5 and Ngfr that have been involved in cell death or
neuroprotection. These commonly regulated genes may thus
represent molecular targets of interest for antiparkinsonian
therapies.
In conclusion, this study provides evidence that STN-HFS in
hemiparkinsonian rats induces widespread molecular changes in
the striatum, suggesting important anatomo-functional remodel-
ing, in particular expression of genes involved in plasticity/
neuroprotection pathways that might create an environment
favorable for protection/sprouting of DA terminals or adult
neurogenesis. Our data also point to genes of the immune system
as potentially involved in LIDs and to adrenergic b1-receptor as a
common player of antiparkinsonian therapies.
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